CA2057828A1 - Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines - Google Patents

Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines

Info

Publication number
CA2057828A1
CA2057828A1 CA002057828A CA2057828A CA2057828A1 CA 2057828 A1 CA2057828 A1 CA 2057828A1 CA 002057828 A CA002057828 A CA 002057828A CA 2057828 A CA2057828 A CA 2057828A CA 2057828 A1 CA2057828 A1 CA 2057828A1
Authority
CA
Canada
Prior art keywords
lipopeptides
fragment
lymphocyte
cytotoxic
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002057828A
Other languages
French (fr)
Other versions
CA2057828C (en
Inventor
Christophe Boutillon
Frederic Martinon
Christian Sergheraert
Remy Magne
Helene Gras-Masse
Elisabeth Gomard
Andre Tartar
Jean-Paul Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9403372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2057828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2057828A1 publication Critical patent/CA2057828A1/en
Application granted granted Critical
Publication of CA2057828C publication Critical patent/CA2057828C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cytotoxic lymphocyte-inducing lipopeptides com-prising a peptide part having between 10 and 40 amino acids approximately and comprising at least one antigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups.

Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene of HIV viruses, in particular the 312-327 fragment or the 302-336 fragment of this protein.
CA002057828A 1990-12-18 1991-12-17 Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines Expired - Fee Related CA2057828C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9015870 1990-12-18
FR9015870A FR2670787B1 (en) 1990-12-18 1990-12-18 LIPOPEPTIDES INDUCING CYTOTOXIC T CELLS AND USE AS VACCINES.

Publications (2)

Publication Number Publication Date
CA2057828A1 true CA2057828A1 (en) 1992-06-19
CA2057828C CA2057828C (en) 2007-06-12

Family

ID=9403372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002057828A Expired - Fee Related CA2057828C (en) 1990-12-18 1991-12-17 Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines

Country Status (10)

Country Link
EP (3) EP1065212A3 (en)
JP (2) JP3821305B2 (en)
AT (1) ATE185148T1 (en)
CA (1) CA2057828C (en)
DE (1) DE69131662T2 (en)
DK (1) DK0491628T3 (en)
ES (1) ES2137160T3 (en)
FR (1) FR2670787B1 (en)
GR (1) GR3031889T3 (en)
SG (1) SG63621A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547681A2 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide
FR2771640B1 (en) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med MIXED MICELLES OF LIPOPEPTIDES FOR INDUCING AN IMMUNE RESPONSE AND THEIR USES FOR THERAPEUTIC PURPOSES
FR2776926B1 (en) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med LYMPHOCYTARY T CYTOTOXICITY T INDUCING LIPOPEPTIDES CARRYING AT LEAST ONE AUXILIARY T EPITOPE, AND THEIR USES FOR VACCINATION
FR2821556B1 (en) * 2001-03-02 2003-04-25 Aventis Pasteur USE OF LIPOPEPTIDES FOR IMMUNOTHERAPY OF HIV + SUBJECTS
WO2002076485A2 (en) 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT1896051E (en) 2005-06-28 2015-01-13 Oncothyreon Inc Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
EP2406290B1 (en) 2009-03-10 2017-07-05 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
ES2584956T3 (en) 2009-03-10 2016-09-30 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CN105837691B (en) 2009-03-10 2021-06-29 贝勒研究院 Antigen presenting cell targeted cancer vaccines
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
AR085573A1 (en) 2011-03-25 2013-10-09 Baylor Res Inst COMPOSITIONS AND IMMUNIZATION METHODS AGAINST THE VIRUS OF HEPATITIS C
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
EP0203676B1 (en) * 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
EP0306912A3 (en) * 1987-09-08 1989-07-05 Albany Medical College Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi

Also Published As

Publication number Publication date
FR2670787B1 (en) 1995-06-23
CA2057828C (en) 2007-06-12
JPH04295498A (en) 1992-10-20
GR3031889T3 (en) 2000-02-29
DE69131662D1 (en) 1999-11-04
EP1065212A2 (en) 2001-01-03
EP0491628A2 (en) 1992-06-24
EP1065212A3 (en) 2001-01-10
SG63621A1 (en) 1999-11-16
JP2004043501A (en) 2004-02-12
DK0491628T3 (en) 2000-04-10
EP0491628B1 (en) 1999-09-29
ATE185148T1 (en) 1999-10-15
JP3821305B2 (en) 2006-09-13
ES2137160T3 (en) 1999-12-16
EP0491628A3 (en) 1992-07-22
DE69131662T2 (en) 2000-04-06
FR2670787A1 (en) 1992-06-26
EP0945461A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
CA2057828A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
CA2224724A1 (en) Subunit vaccine against flavivirus infection
EP0330359A3 (en) Composition useful in the diagnosis and treating of hiv-1 infection
IT1262895B (en) Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes.
GB2255093A (en) Hiv-1 core protein fragments
NO912825D0 (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
CA2088600A1 (en) Herpes simplex virus vp16 vaccines
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
CA2049325A1 (en) Peptide, immunogenic composition and vaccine or medicinal preparation; a method immunising a mammal against lhrh, and a method of improving the meat quality of pigs
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
MXPA02005563A (en) A stable aqua formulation of interferon, the preparation method and the uses thereof.
EP1501936A4 (en) Cytokine protein family
CA2132742A1 (en) Synthetic Peptides and Vaccines Against Parvovirus
NZ316970A (en) Viral recombinant pseudo-particles and vaccinal and anti-tumoral applications
PT91316A (en) PROCESS FOR THE PREPARATION OF RECOMBINANT VECTORS AND HBSAG RECOMBINANT HIBRID PARTICLES HAVING THE MORPHOLOGICAL CHARACTERISTICS OF HBSAG ANTIGENIC CONTAINING AN IMMUNOGENIC SEQUENCE THAT INDUCES HIV-DIRECTING NEUTRALIZING ANTIBODIES OR SUSCEPTIVELY OF RECOGNITION BY SUCH ANTIBODIES
KR910011897A (en) Malaria vaccine
AU7514087A (en) Vaccine containing the protein f of the aids virus
IL93599A0 (en) Kit and/or composition for the prevention or treatment of aids
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
EP1557466A4 (en) Tumor antigen protein and utilization thereof
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
WO1994004565A3 (en) Ipnv vaccine
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
CA2347278A1 (en) Vaccine based on attenuated haemophilus somnus
AU4300700A (en) Inactivated cytokines for immunisation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed